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Introduction
Intracellular aggregates comprising misfolded proteins are a 
common feature of many neurodegenerative diseases. These 
aggregates contain different proteins, depending on the disease, 
and can be seen in different cell types and in different subcellu-
lar compartments. In some cases, mutations in a specific protein 
within the aggregates have been identified, such as α-synuclein 
mutations in Parkinson’s disease (PD) or expanded polygluta-
mine tracts in huntingtin in Huntington’s disease (HD). In other 
cases the major protein species in the aggregates are not mutated. 
While these misfolded proteins may cause pathology via diverse 
mechanisms, in recent years there has been a focus on the role of 
autophagy in these diseases, both as a pathologic mechanism and 
as a therapeutic target.
The term autophagy describes a range of processes, includ-
ing chaperone-mediated autophagy, microautophagy, and mac-
roautophagy. Here we focus on macroautophagy, which we refer 
to as autophagy. In this process, cytoplasmic proteins and orga-
nelles are sequestered into autophagosomes and delivered to the 
lysosomes for degradation. The processes by which autophago-
somes form are described in greater detail elsewhere (1). Briefly, 
autophagosomes form from the coalescence of membrane from 
sources including the plasma membrane, mitochondria, ER, and 
Golgi apparatus. Once formed, autophagosomes are trafficked to 
fuse with the lysosomes, forming autolysosomes; alternatively, 
they may fuse with endosomes to form amphisomes before fusing 
with lysosomes, where their contents are ultimately degraded (1).
In this Review we discuss the evidence that a disruption in 
autophagy might be a contributing factor in aggregate formation 
and the progression of neurodegenerative diseases. We detail 
the ever increasing list of neurodegenerative diseases in which 
autophagy perturbations have been reported and discuss a new 
class of diseases caused by mutations in core autophagy genes. We 
also discuss the ways in which macroautophagy may be upregulat-
ed to reduce levels of the toxic, aggregate-prone, intracytoplasmic 
proteins as a potential therapeutic strategy for these diseases. We 
highlight two major classes of autophagy-modulating drugs, which 
act either via mTOR inhibition or through mTOR-independent 
pathways, and outline recent studies investigating the effective-
ness of these drugs in mouse models of neurodegenerative disease.
Autophagy in the pathogenesis  
of neurodegenerative disease
The importance of autophagy for the brain was highlighted by stud-
ies demonstrating that neuron-specific loss of core autophagy pro-
teins (autophagy-related gene 7 [ATG7] and ATG5) in mice results 
in a neurodegenerative phenotype in the absence of any other 
contributing factors (2, 3). In particular, autophagy is required for 
maintenance of axonal homeostasis, and loss of autophagy results 
in axonal dystrophy (4). Autophagy is also a key regulator of the 
levels of intracytoplasmic, aggregate-prone proteins that cause 
neurodegenerative diseases, including polyglutamine-expanded 
huntingtin (HD) (5), mutant α-synuclein (forms of PD) (6), 
mutant TDP-43 (ALS) (7), and wild-type and mutant tau (vari-
ous dementias) (8). The clearance of such substrates is retarded 
when autophagy is compromised, and clearance is induced when 
autophagy is stimulated. Autophagic dysfunction has now been 
reported in a number of neurodegenerative diseases, which are 
outlined below and summarized in Figure 1.
Alzheimer’s disease. Alzheimer’s disease (AD) is character-
ized by extracellular amyloid-β (Aβ) plaques, which are generated 
through amyloid precursor protein (APP) cleavage, and neurofi-
brillary tangles, comprising paired helical filaments of intracel-
lular, hyperphosphorylated tau, a microtubule-associated protein.
One of the first observations that suggested a role for altered 
autophagy in AD was the accumulation of autophagic vesicles in 
affected neurons (9, 10). While initially considered to represent 
increased autophagy, more recent evidence indicates that this 
accumulation is due to impaired autophagosome clearance. Pre-
senilin-1 (PS1) is part of the γ-secretase complex required for Aβ 
production; however, it also functions to facilitate N-glycosylation 
of the V0a1 subunit of lysosomal vacuolar H+-ATPase (v-ATPase) 
and its trafficking to the lysosome to enable acidification of this 
organelle (11). PS1 and PS2 mutations cause familial autosomal-
dominant AD (12–14) and result in amyloid deposition, neuronal 
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(22, 23). In contrast, loss of autophagy by 
conditional knockout of the autophagy pro-
tein ATG7 in the forebrains of mice results in 
phospho-tau accumulation in a pattern sim-
ilar to a pre-tangle state (24). While deleting 
tau does not prevent inclusion formation, it 
does rescue neurodegeneration in these 
mice (25). Autophagy has been suggested 
to play a major role in the metabolism of Aβ 
(26, 27); however, it may also be important 
in the formation of Aβ. The autophagic ves-
icles that accumulate in AD neurons have 
been shown to be positive for both APP and 
PS1 (10, 28). Furthermore, autophagy has 
been implicated in Aβ secretion, as cross-
ing APP transgenic mice with mice lacking 
Atg7 in forebrain neurons results in less Aβ 
extracellular secretion and plaque forma-
tion (29). Loss of autophagy may therefore 
result in an increase in intracellular Aβ due to both a decrease in 
clearance and a decrease in secretion of the protein. The role of 
autophagy in AD is therefore complex and has been controversial; 
this may be a function of different effects on autophagy at different 
stages of the disease as well as the possibility that autophagy may 
affect different steps of the amyloid life cycle.
PD. PD is characterized by the accumulation of α-synuclein, 
whose levels appear central to pathogenesis, as gene duplications 
of α-synuclein are sufficient to cause PD (30). Increased α-synu-
clein levels in cell culture, Drosophila, and mice inhibit autophagy 
(31) by mislocalizing ATG9, a transmembrane protein with a key 
function in autophagosome formation. Similar autophagy defects, 
including ATG9 mislocalization, have recently been observed in 
cells expressing the VPS35D620N mutation, which causes autoso-
mal-dominant forms of PD (32).
The most common form of autosomal-dominant PD results 
from mutations in the LRRK2 gene (reviewed in ref. 33). It has been 
suggested that LRRK2 negatively regulates autophagy, as autoph-
agy is increased following LRRK2 siRNA knockdown or inhibition 
(34, 35). In contrast, overexpression of both wild-type LRRK2 and 
LRRK2G2019S, but not catalytically inactive forms of the protein, 
induces an AMPK-mediated upregulation of autophagy (36). Other 
studies have reported autophagy upregulation following overexpres-
sion of LRRK2G2019S by an ERK1/2-mediated mechanism (37, 38).
Perhaps the most prominent link between autophagy and 
familial forms of PD comes from studies of the roles of PTEN- 
induced putative kinase 1 (PINK1, also known as PARK6) and Par-
loss, and lysosome pathology (15). Loss of lysosome acidifica-
tion, and therefore lysosome function, results in autophagosome 
accumulation, as autophagosomes do not fuse with dysfunctional 
lysosomes. Rescue of lysosomal defects can restore autophag-
ic activity. For example cAMP treatment decreased lysosomal 
pH in patient fibroblasts (16). Further, deletion of cystatin B (an 
inhibitor of lysosomal cysteine proteases) in an AD mouse model 
enhanced defective lysosomal turnover, promoted Aβ clearance, 
and improved mouse cognitive performance (17).
The autophagy gene BECN1, encoding beclin 1, has reduced 
mRNA levels in AD brain tissue (18, 19). Caspase-3, which may 
be activated in AD neurons, can also cleave beclin 1, resulting in 
impaired autophagosome formation (20). When crossed with 
beclin 1 haploinsufficient mice, mice overexpressing human APP 
exhibited autophagy disruption and enhanced pathology (18). 
Because loss of beclin 1 activity reduces autophagosome forma-
tion, AD may be associated with defects in both autophagosome 
biogenesis and autophagosome degradation as a consequence of 
the lysosomal defects described above.
Beclin 1 disruption may also contribute to AD in non-neu-
ronal cells. Microglia from AD patients have reduced beclin 1 and 
retromer (a key component of the endosomal, protein-sorting 
machinery) levels, with the beclin 1 disruption further altering cor-
rect retromer localization to phagosome membranes and potential 
receptor-mediated phagocytosis (21).
Tau and Aβ, the two key proteins that aggregate in AD, are 
autophagy substrates. Induction of autophagy decreases tau levels 
Figure 1. Intersections of the autophagic 
pathway and neurodegenerative diseases. 
This schematic shows the progression through 
the autophagic pathway from formation of the 
autophagosome to fusion with the lysosome. 
Red text highlights points of compromise in 
the pathway that have been demonstrated in 
neurodegenerative disease, along with examples 
of causes of this compromise.
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port can result in impaired autophagosome-lysosome fusion, as 
shown by autophagosome accumulation with enhanced toxicity 
in cell, Drosophila, and mouse models (63, 64). More recently, 
mutations in DCTN1 have been shown to cause Perry syndrome, 
a neurodegenerative disease that can present with Parkinsonism 
and psychiatric changes (65), suggesting a role for autophagic 
dysfunction in this disease.
HD. HD is caused by polyglutamine repeat expansions in the 
huntingtin (htt) protein (66). A role for autophagy in HD was first 
suggested by observations of increased levels of autophagic mark-
ers in the brains or tissues of HD patients and in mouse models 
of the disease (67–69). In HD mouse models, the key autophagic 
regulator, mTOR, is sequestered into htt aggregates, resulting 
in an inhibition of signaling, consistent with autophagy induc-
tion (70). While this would appear to suggest an upregulation of 
autophagy in HD, the situation may in fact be more complicated. 
The positive autophagy regulator, beclin 1, has also been shown 
to be sequestered into htt aggregates (71), which would negatively 
affect autophagosome formation. Moreover, the accumulated 
autophagosomes observed may not be fully functional; they have 
been shown to be relatively empty due to inefficient sequestration 
of cargo, in particular organelles such as mitochondria and lipid 
droplets, and the increase in autophagosome number is not asso-
ciated with an increase in protein degradation (72).
In addition, htt itself may control autophagy through a variety 
of different mechanisms. Two htt-interacting proteins, Rab5 and 
Rhes, are positive regulators of autophagy (73, 74), and htt lacking 
the polyglutamine repeat region induces autophagy and is protec-
tive against toxicity of mutant polyglutamine–expanded htt in cells 
and mice (75), suggesting a more direct role for htt in autophagy.
While it is not yet clear whether alterations in autophagy are 
primary factors in the pathogenesis of HD, polymorphisms in the 
core autophagy gene, ATG7, have been suggested to be associated 
with earlier age of onset (76).
Hereditary spastic paraplegia. Hereditary spastic paraplegias 
(HSPs) include a broad group of neurodegenerative diseases 
involving degeneration associated with the lower extremities. 
Two forms of HSP have been associated with mutations in genes 
with a role in autophagy. The first identified was TECPR2, a posi-
tive autophagy regulator that interacts with LC3 (77, 78). The exact 
function of this protein is unknown; however, it bears homology 
to TECPR1, which has been implicated in sequestration of bacte-
ria into autophagosomes, suggesting a role as an autophagy adap-
tor (77). Type 15 HSP is caused by mutations in ZFYVE26 (79) 
encoding spastizin (also known as FYVE-CENT), which interacts 
with the core autophagy protein, beclin 1. Disease-associated 
mutations in spastizin compromise this interaction, leading to 
impaired autophagy (79).
Lafora disease. Lafora disease is an autosomal recessive myo-
clonous epilepsy resulting in early death due to neurodegenera-
tion. Its pathologic hallmark is the accumulation of Lafora bodies 
(LBs), comprising abnormally hyperphosphorylated polyglucosan 
with a smaller polyubiquitinated protein component. Most muta-
tions in Lafora disease occur in two proteins, laforin and malin, 
which form a complex that, when disrupted, drives the disease 
(reviewed in ref. 80). LB accumulation may be partly the result 
of altered carbohydrate metabolism (81). However, data from 
kin RBR E3 ubiquitin protein ligase (PARK2, also known as Parkin) 
in mitophagy (reviewed in ref. 39). Loss-of-function mutations in 
Parkin and PINK1 cause autosomal-recessive and sporadic juve-
nile-onset PD (40–42). These proteins regulate mitophagy, a pro-
cess whereby damaged mitochondria are degraded. PINK1 associ-
ates with damaged mitochondria when membrane potential is lost 
(43, 44), followed by activation of the E3 ubiquitin ligase, Parkin, 
which ultimately mediates mitophagy. Despite many studies in 
cell culture with overexpression of these proteins showing effects 
on mitochondrial clearance, the consequences of loss of Parkin 
for mitophagy in vivo have been questioned (45). In addition to a 
role in mitophagy, Parkin has also been suggested to be involved in 
autophagic clearance of α-synuclein, as Parkin overexpression in a 
rat model system promoted autophagic clearance of toxic proteins 
including α-synuclein (46).
An autosomal-recessive form of Parkinsonism, Kufor–Rakeb 
syndrome, is caused by mutations in ATPase type 13A2 (ATP13A2, 
also known as PARK9), which encodes a lysosomal ATPase (47). 
ATP13A2 regulates lysosomal acidification, which is necessary 
for autophagosome-lysosome fusion and subsequent substrate 
degradation, and cells lacking ATP13A2 or patient fibroblasts with 
ATP13A2 mutations displayed defects in these processes (48)
ALS. ALS is the most common form of motor neuron dis-
ease (49). ALS is generally a sporadic disease, but 20% of cases 
are familial and have been associated with an increasing number 
of genes. One of these, sequestosome 1 (SQSTM1), encodes the 
scaffold protein p62; both point mutations and deletions have 
been identified in ALS cases (50, 51). In addition to its genetic 
involvement in ALS, p62 is commonly found in aggregates in 
multiple neurodegenerative diseases, and mutations in SQSTM1 
have been identified in Paget’s disease of the bone (52). p62 acts 
as an adaptor to bind ubiquitinated targets to autophagosome- 
associated lipidated microtubule–associated light chain 3 (LC3-
II) for engulfment by autophagosomes (53). While this suggests a 
clear link between autophagy and ALS, p62 mutations are located 
throughout the protein, across multiple domains (51), and their 
effect on autophagy has yet to be fully established. This is also true 
for ALS-causing mutations in another adaptor, optineurin (54). 
Optineurin has established roles in xenophagy, a form of autoph-
agy that degrades foreign pathogens (55). Optineurin can also bind 
to protein aggregates (56) and is sequestered in inclusions in ALS 
patients as well as in other neurodegenerative diseases (57, 58).
The most common known mutation in ALS is an intronic hex-
anucleotide repeat expansion in the gene C9ORF72. Very little is 
known about the function of the C9ORF72 protein, and it is cur-
rently unclear whether the disease resulting from this mutation is 
due to a loss of function, gain of function, or both. However pre-
liminary studies on the protein’s function suggest that it may have 
a role in endocytic trafficking and localizes with autophagosomes 
(59). siRNA knockdown of C9ORF72 increased LC3-II levels, 
although the study did not fully characterize the meaning of this 
in terms of autophagy function (59).
Yet another ALS-causing gene with a clear function in autoph-
agy is dynactin 1 (DCTN1) (60). Autophagosomes are formed 
throughout neurons, and their efficient movement to lysosome-
rich areas for fusion and cargo degradation is dependent on 
dynein-mediated transport (61, 62). A reduction in this trans-
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both intracytoplasmic aggregates and associated cell death. Addi-
tionally, autophagy also protects against both proapoptotic (95, 
96) and pro-necrotic (97) insults, which may contribute to its ben-
efits. The protective effect seen from autophagy induction in cell 
models has been successfully translated into a range of animal 
models, in Drosophila melanogaster models of both tauopathies 
(8) and HD (70, 98), and also in mammalian models of disease, 
including HD, spinocerebellar ataxia type III, tauopathy, PD, and 
even familial prion disease (see Table 1 for studies of autophagy 
upregulation in mouse models of neurodegeneration). Together 
these studies demonstrate that autophagy upregulation and pro-
motion of aggregation-prone protein degradation ameliorate 
neurodegenerative pathology.
It is important to note that autophagy inducers are unlikely 
to be panaceas for all neurodegenerative diseases. Indeed, in 
diseases associated with impaired autophagosome clearance 
(e.g., lysosome storage diseases), it is possible that induction of 
autophagosome biogenesis may be deleterious due to a build-
up of autophagosomes that are not cleared effectively. A greater 
understanding of the potential mechanisms of autophagic dys-
function in neurodegenerative disease as outlined in the first part 
of this Review is therefore vital for development of therapeutics.
Mechanisms of autophagy upregulation
The autophagy-modulating agents used in preclinical trials in 
models of neurodegenerative disease have diverse mechanisms 
of action. Our understanding of how many of these agents work 
is not complete; however, they can be divided into mTOR-depen-
dent and mTOR-independent agents.
mTOR-dependent pharmacologic agents. mTOR is found in two 
different functional complexes. mTOR complex 1 (mTORC1) is a 
negative autophagy regulator, and mTORC2 is a positive regula-
tor (99). The allosteric mTORC1 inhibitor rapamycin was the first 
drug to be identified as an autophagy inducer (100, 101). Rapa-
mycin forms a complex with FK506-binding protein 12 (FKBP12), 
which binds to and inhibits the kinase activity of mTORC1 (102, 
103). mTORC1 inhibition induces autophagosome formation, as 
this kinase phosphorylates and inhibits core autophagy proteins 
such as Unc-51 like autophagy activating kinase 1/2 (ULK1/2) 
and ATG13 (104–106). Although the mTOR pathway is involved 
in a wide range of cellular functions (reviewed in ref. 107), the 
therapeutic effects of rapamycin in models of neurodegenera-
tive disease are predominantly autophagy mediated (8, 98). The 
limited absorption of rapamycin has driven the development of 
many so-called rapalogs such as temsirolimus (CCI-779), everoli-
mus (RAD001), and ridaforolimus (AP23573). To date, it is these 
rapalogs that have been investigated most widely in terms of 
their potential therapeutic value in neurodegenerative diseases. 
Newly developed mTOR inhibitors include the ATP-competitive 
mTOR inhibitors (reviewed in ref. 108). Torin1 directly inhibits 
both mTORC1, including the rapamycin-resistant functions, and 
mTORC2 (109). Inefficacious concentrations of ATP-competitive 
mTOR inhibitors can be combined with rapamycin treatment 
to give complete and selective inhibition of mTORC1, leaving 
mTORC2 signaling intact (110), which could prove a powerful 
means of achieving mTOR-dependent autophagy upregulation. 
This is particularly important, as long-term use of mTORC1/2 
patient and animal models clearly support a role for disrupted 
autophagy in disease onset and progression. Overexpression of 
laforin induces autophagy, while a reduction in laforin levels has 
the opposite effect (82). Both laforin- and malin-deficient mice 
show an early defect in autophagosome biogenesis, which may 
lead to LB formation (83–85). Both mouse models show reduced 
levels of autophagosomes and a reduction in total and autophagy-
dependent protein degradation.
Neurodegenerative disorders associated with mutations in core 
autophagy genes. The likelihood that autophagy defects contribute 
to neurodegeneration is supported by recent studies that reveal 
a class of diseases caused by mutations in core autophagy genes. 
Neurodegeneration with brain iron accumulation 5 (NBIA5; 
OMIM identifier 300894) is a neurodegenerative disease that 
presents with movement disorder and intellectual decline. It is 
currently described as β-propeller protein–associated neurode-
generation (BPAN) or static encephalopathy of childhood with 
neurodegeneration in adulthood (SENDA) (86). BPAN is an 
X-linked dominant disease with loss-of-function mutations iden-
tified in the β-propeller scaffold protein–encoding WDR45/WIPI4, 
a core autophagy gene that is one of four homologs of yeast Atg18. 
BPAN appears to be a sporadic disease, with mutations in WIPI4 
occurring de novo, as parents and siblings in 20 subjects did not 
share the mutations (86). In lymphoblastoid cell lines from five 
patients, reduced autophagic activity and an accumulation of 
aberrant ATG9A and LC3-II positive autophagic structures were 
reported (87). This may be a direct result of disrupted ATG9A vesi-
cle translocation at the autophagosome formation site (88) due to 
altered WIPI4 activity in autophagosome formation (89, 90).
Another disease caused by an autophagy gene defect is Vici syn-
drome (OMIM identifier 242840), a multisystem disorder associat-
ed with callosal agenesis. This disorder is caused by recessive muta-
tions in EPG5, an autophagy gene identified first in Caenorhabditis 
elegans (91). Epg5-null mice develop ALS-like features (92).
Autophagy upregulation as therapy  
for neurodegenerative disease
The evidence outlined above suggests a possible role for autoph-
agic dysfunction in the pathogenesis of neurodegenerative 
diseases, but autophagy also has the ability to decrease the 
accumulation of toxic, aggregate-prone proteins that cause 
neurodegeneration. These aggregate-prone proteins are fre-
quently substrates for both the ubiquitin-proteasome system 
and autophagy as monomers. However, because the oligomeric 
forms of these proteins cannot pass through the narrow entrance 
of the proteasome, such higher-order species may be targeted to 
autophagy. While the appearance of intracytoplasmic inclusions 
is reduced by autophagy upregulation, our working model is that 
autophagy does not clear the large aggregates directly, but rather 
clears the soluble aggregate precursors, shifting the equilibrium 
from aggregate formation toward degradation (93).
Multiple studies provide proof of principle for the modulation 
of autophagy as a therapy for neurodegenerative disease. In vitro 
work examining the effect of autophagy upregulation on the clear-
ance of a wide range of aggregation-prone proteins including those 
with polyQ and polyA expansions (5, 8), mutant tau and ataxin-3 
(8), and mutant α-synuclein (6, 94) has suggested reductions in 
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itors unsuitable as therapy for neurodegenerative disease (117). 
PI103 is reported not to induce significant apoptosis in cultured 
cells (118) but is unsuitable for clinical development due to its 
rapid in vivo metabolism (116).
mTOR-independent pharmacologic agents. mTOR signaling has 
diverse autophagy-independent functions, including ribosome 
biogenesis and metabolism (reviewed in ref. 107). Were mTOR-
dependent autophagy induction to be used as long-term therapy 
for neurodegenerative disease, this would result in non-trivial side 
effects (immunosuppression and impaired wound healing, for 
example). Consequently, much work has been dedicated to iden-
tifying mTOR-independent upregulators of autophagy. One such 
study identified several US FDA-approved drugs that ameliorate 
neurodegenerative pathology in cell, Drosophila, and zebrafish 
models of HD via mTOR-independent upregulation of autophagy 
(119). These compounds revealed cyclical regulation of autophagy 
by the cAMP/EPAC/PLCε/Ins(1,4,5)P3 pathway, together with the 
catalytic inhibitors impair autophagosome biogenesis (99), raising 
concerns about the most suitable exposure durations of such drugs 
in the context of neurodegenerative diseases.
In addition to the drugs that directly inhibit mTOR, other 
drugs act indirectly through the mTOR pathway. For example, 
stimulation of the AMPK pathway can upregulate autophagy in an 
mTOR-dependent manner (111). One example of an AMPK acti-
vator with therapeutic potential in neurodegenerative disease is 
metformin (commonly used in type 2 diabetes) (112). Nilotinib, 
which has been shown to be protective in multiple mouse models 
of neurodegeneration through different mechanisms (113, 114), 
can also induce autophagy via AMPK activation (115). Dual class I 
PI3K/mTORC1 inhibitors such as PI103 are potent mTOR-depen-
dent autophagy inducers, which address the negative feedback 
between mTORC1 and the class I PI3K/AKT pathway (116). How-
ever, concerns have been raised that AKT inhibition may increase 
susceptibility to cell death, rendering class I PI3K/mTORC1 inhib-
Table 1. Therapeutic upregulation of autophagy in transgenic mouse models of neurodegenerative disease
Transgenic mouse model of neurodegeneration Autophagy upregulation agent(s) Aggregate-prone protein cleared ReferenceA
HD
HD-N171-82Q (mice express 171 amino acid N-terminal 
fragment of htt with 82 glutamines)
Temsirolimus (CCI-779, rapalog), rilmenidine Mutant htt 70, 121
PD
D-Line (mice express wild-type human α-synuclein) Lentivirus-mediated delivery of beclin 1, lentivirus-mediated  
delivery of Atg7 or rapamycin
Wild-type α-synuclein 94, 132
mThy1 (mice express wild-type human α-synuclein) LDN-57444 (ubiquitin carboxyterminal  
hydrolase L1 inhibitor) 
Wild-type α-synuclein 133
A53T (mice express A53T human α-synuclein in CNS 
neurons)
Nilotinib (tyrosine kinase inhibitor) Mutant α-synuclein 114
AD
CRND8 APP (mice express human APP with the Swedish 
and Indiana mutations)
Latrepirdine Mutant Aβ and wild-type  
α-synuclein
134
J20 APP (mice express human APP with Swedish and 
Indiana mutations)
Lentivirus-mediated delivery of beclin 1, rapamycin Mutant Aβ 18, 135
SwDI APP (mice express human APP with Swedish, Dutch, 
and Iowa mutations)
Nilotinib (tyrosine kinase inhibitor) Mutant Aβ 113
APP/PS1 (mice express human APP with Swedish mutation, 
plus human PSEN1 exon 9 deleted)
Resveratrol (AMPK activator), arctigenin,  
temsirolimus (CCI-779)
Mutant Aβ 136–139
3xTg-AD (mice express human APP with Swedish mutation, 
human P301L tau, and M146V PSEN1)
Rapamycin, GTM-1 (quinazoline derivative) Mutant Aβ and mutant tau 140–142
Tauopathy
PK–/–/Tau (VLW) (mice express human mutated tau protein 
with deletion of Parkin)
Trehalose Mutant tau 125
P301S tau mice, various lines (express human P301S tau) Methylthioninium chloride (methylene blue),  
lithium, trehalose, rapamycin
Mutant tau 126, 143–146
FTLD
FTLD-U (mice overexpress mouse TDP-43 in the forebrain) Rapamycin, spermidine, carbamazepine, tamoxifen Wild-type TDP-43 147
Prion disease
PrP-A116V (mice express mouse prion protein with A116V 
mutation and 128V polymorphism)
Rapamycin Mutant PrP 147, 148
SCA3
Ataxin-3, various lines (mice express human ataxin-3 with 
an expanded polyglutamine repeat region)
Temsirolimus (CCI-779), 17-DMAG (Hsp 90 inhibitor) Mutant ataxin-3 149, 150
AInclusion criteria were studies that demonstrated upregulation of autophagy and/or increased aggregate clearance in a transgenic mouse model of 
neurodegeneration in response to treatment.
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Ca2+/calpain/Gsα pathway (see Figure 2 and ref. 119) and showed 
some overlap with FDA-approved drugs identified in a concurrent 
screen (120). One of these drugs was the centrally acting antihy-
pertensive rilmenidine, which acts via Gi-coupled imidazoline 
receptors (widely distributed in the brain) to reduce cAMP levels 
(119). Subsequently, rilmenidine was shown to promote clear-
ance of aggregate-prone proteins and improve neurodegenerative 
pathology in both primary neurons and a transgenic mouse model 
of HD (121). In light of these results, together with the fact that 
rilmenidine is safe and suitable for long-term use, a safety trial is 
ongoing in patients with HD (EudraCT number 2009-018119-14). 
Other drugs that act through the cAMP/EPAC/PLCε-Ins(1,4,5)P3 
pathway include the mood stabilizers lithium (122), carbamaz-
epine, and valproic acid (119). These drugs induce autophagy by 
reducing Ins(1,4,5)P3 levels via the phosphoinositol cycle; lithium 
inhibits inositol monophosphatase (122), while carbamazepine 
and valproic acid inhibit inositol synthesis (119). Subsequent stud-
ies have proposed that reducing Ins(1,4,5)P3 levels might result in 
less mitochondrial uptake of Ins(1,4,5)P3 receptor–released Ca2+ 
and downstream AMPK activation (123), which can occur without 
mTORC1 inhibition. With regard to the Ca2+/calpain/Gsα pathway, 
several FDA-approved L-type Ca2+ channel antagonists, including 
verapamil, nitrendipine, and amiodarone, together with inhibi-
tors of calpain activation such as calpeptin and calpastatin, have 
been found to promote the clearance of aggregation-prone pro-
teins by autophagy (119).
There are also many compounds with therapeutic potential 
as mTOR-independent autophagy inducers in neurodegenerative 
disease for which the mechanism of action is under characterized. 
One example is the disaccharide trehalose, which promotes clear-
ance of mutant htt and mutant α-synuclein in mammalian cell 
culture (124), as well as mutant tau in transgenic mouse models 
(125–128). Trehalose is neuroprotective in mouse tauopathy mod-
els (125, 126) and can improve motor and cognitive performance 
(125). In ALS mouse models, trehalose has been shown to prolong 
life span (126, 127).
Future directions
Given the therapeutic potential of autophagy upregulation in 
neurodegenerative disease, there is a clear need to develop more 
specific autophagy modulators with more tightly defined mecha-
nisms of action. This would enable targeted counteraction of the 
autophagy deficit present in a particular neurodegenerative con-
dition. However, drug discovery and characterization are slow 
processes. In the meantime, strategies should be developed to 
maximize autophagy upregulation with currently available agents, 
Figure 2. Points of action of autophagy-upregulating agents. This simplified schematic shows some of the pathways known to control autophagy and 
indicates where drugs and other agents act that are used to upregulate autophagy. In the interest of clarity, not all interactions of these pathways are 
shown. Both the mTOR-dependent and mTOR-independent pathways negatively regulate the autophagic process, and inhibition of these pathways 
will lead to an upregulation of autophagy. In the case of mTOR, this may occur through relieving the inhibition of the ULK1 complex, which is a positive 
regulator of autophagy. In the case of mTOR-independent regulation, the points of interaction between many agents in this category and the autophagy 
machinery are not known.
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while minimizing deleterious side effects. One promising approach 
is the simultaneous induction of autophagy by mTOR-dependent 
and mTOR-independent pathways. As a proof of principle, com-
bined rapamycin and lithium treatment in a Drosophila model of 
HD induced autophagy and reduced neurodegenerative pathol-
ogy to a greater extent than either drug alone (129). Additionally, 
combined rapamycin and trehalose treatment exerts an additive 
effect on the clearance of mutant htt and mutant α-synuclein by 
autophagy (124). In addition to small molecules, autophagy upreg-
ulation may be amenable with peptide strategies, which may have 
promise in neurodegeneration (130).
It is also important to be mindful of other therapies for neurode-
generative disease that might impede the clearance of pathogenic 
aggregation-prone proteins by autophagy. For instance, antioxidants 
have been used to counteract the increased oxidative stress seen in 
many neurodegenerative diseases, but some classes of antioxidants 
are reported to counteract the beneficial effects of autophagy induc-
tion in Drosophila and zebrafish models of HD (131).
In conclusion, therapeutic strategies aimed at upregulation of 
autophagy appear promising. As our knowledge of the pathways 
controlling this process increases, we are likely to be able to devel-
op ever more selective therapies that will upregulate autophagy in 
a manner that will be optimal for the specific disease to be treated.
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